These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25465236)

  • 1. Global connectivity of hub residues in Oncoprotein structures encodes genetic factors dictating personalized drug response to targeted Cancer therapy.
    Soundararajan V; Aravamudan M
    Sci Rep; 2014 Dec; 4():7294. PubMed ID: 25465236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.
    Vela CM; Knepper TC; Gillis NK; Walko CM; McLeod HL; Hicks JK
    Pharmacotherapy; 2017 Sep; 37(9):1043-1051. PubMed ID: 28235141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The energy landscape analysis of cancer mutations in protein kinases.
    Dixit A; Verkhivker GM
    PLoS One; 2011; 6(10):e26071. PubMed ID: 21998754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrostatic explanation of D1228V/H/N-induced c-Met resistance and sensitivity to type I and type II kinase inhibitors in targeted gastric cancer therapy.
    Xu Z; Hu P; Fang D; Ni L; Xu J
    J Mol Model; 2019 Jan; 25(1):13. PubMed ID: 30607513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular basis of targeting protein kinases in cancer therapeutics.
    Tsai CJ; Nussinov R
    Semin Cancer Biol; 2013 Aug; 23(4):235-42. PubMed ID: 23651790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
    Park HS; Lim SM; Kim S; Kim S; Kim HR; Kwack K; Lee MG; Kim JH; Moon YW
    PLoS One; 2016; 11(4):e0154133. PubMed ID: 27105424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
    Gerhards NM; Rottenberg S
    Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of germline and somatic missense variations on drug binding sites.
    Yan C; Pattabiraman N; Goecks J; Lam P; Nayak A; Pan Y; Torcivia-Rodriguez J; Voskanian A; Wan Q; Mazumder R
    Pharmacogenomics J; 2017 Mar; 17(2):128-136. PubMed ID: 26810135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covalent targeting of acquired cysteines in cancer.
    Visscher M; Arkin MR; Dansen TB
    Curr Opin Chem Biol; 2016 Feb; 30():61-67. PubMed ID: 26629855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemogenomic screening identifies the Hsp70 co-chaperone DNAJA1 as a hub for anticancer drug resistance.
    Nitika ; Blackman JS; Knighton LE; Takakuwa JE; Calderwood SK; Truman AW
    Sci Rep; 2020 Aug; 10(1):13831. PubMed ID: 32796891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.
    Garralda E; Paz K; López-Casas PP; Jones S; Katz A; Kann LM; López-Rios F; Sarno F; Al-Shahrour F; Vasquez D; Bruckheimer E; Angiuoli SV; Calles A; Diaz LA; Velculescu VE; Valencia A; Sidransky D; Hidalgo M
    Clin Cancer Res; 2014 May; 20(9):2476-84. PubMed ID: 24634382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology.
    Zolotovskaia MA; Sorokin MI; Petrov IV; Poddubskaya EV; Moiseev AA; Sekacheva MI; Borisov NM; Tkachev VS; Garazha AV; Kaprin AD; Shegay PV; Giese A; Kim E; Roumiantsev SA; Buzdin AA
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies.
    Patterson SE; Liu R; Statz CM; Durkin D; Lakshminarayana A; Mockus SM
    Hum Genomics; 2016 Jan; 10():4. PubMed ID: 26772741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
    Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
    PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-Based Precision Oncology with the Cancer Targetome.
    Blucher AS; Choonoo G; Kulesz-Martin M; Wu G; McWeeney SK
    Trends Pharmacol Sci; 2017 Dec; 38(12):1085-1099. PubMed ID: 28964549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
    Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
    Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Tumor Boards in Clinical Practice.
    Luchini C; Lawlor RT; Milella M; Scarpa A
    Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.